Drug intelligence / Profile preview

F027

Development stage: Phase 3
Lead developer: Shandong New Time Pharmaceutical
Modality: Peptides
Administration: Subcutaneous

Overview

F027 is a drug candidate developed by Shandong New Time Pharmaceutical Co., LTD, currently in Phase III clinical trials for the treatment of Type 2 Diabetes. It is described as a semaglutide formulation and functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. Administered as a once-weekly subcutaneous injection, F027 aims to improve glycemic control in patients with Type 2 Diabetes, similar to the established drug Ozempic® (semaglutide).

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on F027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F027.

Explore the full profile